Recent data support preventive multivessel PCI in STEMI patients
EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS
Investigators from the HORIZONS-AMI trial also recently evaluated the effect of a CTO in a non–infarct-related artery. The study population included 3,283 patients undergoing primary PCI for STEMI. The 283 patients with multivessel disease and a CTO in a non–infarct-related artery had an adjusted 2.88-fold greater 30-day mortality and 2.27-fold greater 3-year mortality than those with single-vessel disease. The 1,477 patients with multivessel disease but no CTO had a 1.75-fold greater 30-day mortality than those with single-vessel disease, but no increased risk through 3 years (Eur. Heart J. 2012;33:768-75).
"Does this mean you should bring patients back to do the CTO? Probably. We don’t do that enough, but probably that’s indeed the case," Dr. Holmes commented.
He reported having no financial conflicts of interest.
